Literature DB >> 11488953

Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation.

M Pistis1, G Porcu, M Melis, M Diana, G L Gessa.   

Abstract

Cannabinoids activate the firing of mesoprefrontocortical dopamine neurons and release dopamine in the prefrontal cortex. This study was undertaken with the aim of clarifying the interaction between cannabinoids and mesocortical system in the prefrontal cortex. The effect of Delta9-tetrahydrocannabinol (Delta9-THC) and the synthetic CB1 agonist WIN55,212-2 (WIN) was studied by extracellular single unit recordings, in chloral hydrate anaesthetised rats, on the spontaneous activity of pyramidal neurons and on the inhibition produced on these neurons by the electrical stimulation of the ventral tegmental area (VTA). Intravenously administered Delta9-THC and WIN (1.0 and 0.5 mg/kg, respectively), increased the firing rate of pyramidal neurons projecting to the VTA. VTA stimulation produced a phasic inhibition (167 +/- 6 ms) in 79% of prefrontal cortex pyramidal neurons. Delta9-THC and WIN reverted this inhibition in 73% and 100% of the neurons tested, respectively. The subsequent administration of the selective CB1 antagonist SR141716A (1 mg/kg) readily suppressed the effects of both cannabinoids and restored the inhibitory response to VTA stimulation. Moreover, when administered alone, SR141716A prolonged the inhibition in 55.6% of the neurons tested. The results indicate that stimulation of CB1 receptors by cannabinoids results in an enhanced excitability of prefrontal cortex pyramidal neurons as indexed by the suppression of the inhibitory effect of VTA stimulation and by the increase in firing rate of antidromically identified neurons projecting to the VTA. Furthermore, our results support the view that endogenous cannabinoids exert a negative control on dopamine activity in the prefrontal cortex. This study may be relevant in helping to understand the influence of cannabinoids on cognitive processes mediated by the prefrontal cortex.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11488953     DOI: 10.1046/j.0953-816x.2001.01612.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  21 in total

Review 1.  Endocannabinoids and exercise.

Authors:  A Dietrich; W F McDaniel
Journal:  Br J Sports Med       Date:  2004-10       Impact factor: 13.800

2.  The endocannabinoid system modulates the valence of the emotion associated to food ingestion.

Authors:  Mónica Méndez-Díaz; Pavel Ernesto Rueda-Orozco; Alejandra Evelyn Ruiz-Contreras; Oscar Prospéro-García
Journal:  Addict Biol       Date:  2010-12-23       Impact factor: 4.280

3.  AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.

Authors:  Mark D Black; Rachel J Stevens; Nancy Rogacki; Robert E Featherstone; Yaw Senyah; Odessa Giardino; Beth Borowsky; Jeanne Stemmelin; Caroline Cohen; Philippe Pichat; Michal Arad; Segev Barak; Amaya De Levie; Ina Weiner; Guy Griebel; Geoffrey B Varty
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

4.  Alterations in behavioral flexibility by cannabinoid CB1 receptor agonists and antagonists.

Authors:  Matthew N Hill; Larissa M Froese; Anna C Morrish; Jane C Sun; Stan B Floresco
Journal:  Psychopharmacology (Berl)       Date:  2006-06-03       Impact factor: 4.530

5.  Cannabinoids elicit antidepressant-like behavior and activate serotonergic neurons through the medial prefrontal cortex.

Authors:  Francis Rodriguez Bambico; Noam Katz; Guy Debonnel; Gabriella Gobbi
Journal:  J Neurosci       Date:  2007-10-24       Impact factor: 6.167

Review 6.  Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks.

Authors:  Mason M Silveira; Jonathon C Arnold; Steven R Laviolette; Cecilia J Hillard; Marta Celorrio; María S Aymerich; Wendy K Adams
Journal:  Neurosci Biobehav Rev       Date:  2016-09-14       Impact factor: 8.989

7.  Astrocytic Mechanisms Involving Kynurenic Acid Control Δ9-Tetrahydrocannabinol-Induced Increases in Glutamate Release in Brain Reward-Processing Areas.

Authors:  Maria E Secci; Paola Mascia; Claudia Sagheddu; Sarah Beggiato; Miriam Melis; Andrea C Borelli; Maria C Tomasini; Leigh V Panlilio; Charles W Schindler; Gianluigi Tanda; Sergi Ferré; Charles W Bradberry; Luca Ferraro; Marco Pistis; Steven R Goldberg; Robert Schwarcz; Zuzana Justinova
Journal:  Mol Neurobiol       Date:  2018-08-27       Impact factor: 5.590

8.  Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys.

Authors:  David R Schulze; F Ivy Carroll; Lance R McMahon
Journal:  Psychopharmacology (Berl)       Date:  2012-02-29       Impact factor: 4.530

Review 9.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

Review 10.  Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate.

Authors:  K Rea; M Roche; D P Finn
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.